Latest news with #nasalspray
The Guardian
4 days ago
- Health
- The Guardian
From pollen counts to pollen bombs: take our hay fever quiz to find out how much you know about this time of year
Buy Beconase now on Amazon *For the treatment of hayfever and symptomatic relief from nasal congestion, runny nose, sneezing, itchy nose, eye symptoms (such as itching, watering, redness) and associated sinus discomfort in adults aged 18 and over. Beconase Hayfever Relief for Adults 0.05% Nasal Spray contains beclometasone dipropionate. Always read the leaflet. MAT-9521
Globe and Mail
4 days ago
- Business
- Globe and Mail
PharmAla Biotech Warns Against Fake Products Claiming to be Made by PharmAla
TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (' PharmAla ' or the ' Company ') (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), has become aware of unknown parties illegally retailing a nasal spray online, falsely claiming to be a PharmAla Biotech product and unlawfully using PharmAla logos and trademarks. PharmAla is issuing this warning in order to protect consumers and patients. PharmAla's LaNeo MDMA drug products are exclusively available through a qualified practitioner's prescription and Health Canada authorization and administered under the oversight of medical professionals. PharmAla does not, and will not, sell any products directly to consumers; PharmAla does not currently produce a nasal spray. The contents of any nasal spray purporting to be made by PharmAla are unknown and could be harmful to human health. PharmAla strongly urges any and all users who have purchased any unauthorized product to responsibly dispose of it immediately. PharmAla Biotech's mission remains unchanged: to support individuals with legitimate medical needs with the supply of clinical grade LaNeo™ MDMA through legal and regulated channels. We will continue to advance this mission through our work with clinical trials and Health Canada's Special Access Program (SAP). Qualified medical practitioners seeking access for their patients through the SAP can submit applications directly to Health Canada. Practitioners are also encouraged to register through our dedicated portal at: For more details on Health Canada's Special Access Program for psychedelic-assisted psychotherapy, visit: If you have questions about obtaining legitimate PharmAla products, the special access program, or wish to report suspicious products claiming association with our brand, please reach out to us directly for more information and assistance. About PharmAla PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials as well as commercial sales in selected jurisdictions, and to develop novel drugs in the same class. PharmAla is the only company currently provisioning clinical-grade MDMA for patient treatments outside of clinical trials. PharmAla's research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. PharmAla is a 'regulatory first' organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators. For more information, please contact: Nicholas Kadysh Chief Executive Officer PharmAla Biotech Holdings Inc. Email: press@ Phone: 1-855-444-6362 Website: Neither the CSE nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking statements. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as 'plans', 'strategy', 'expects' or 'does not expect', 'intends', 'continues', 'anticipates' or 'does not anticipate', or 'believes', or variations of such words and phrases or may contain statements that certain actions, events or results 'will be taken', 'will launch' or 'will be launching', 'will include', 'will allow', 'will be made' 'will continue', 'will occur' or 'will be achieved'. The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding the use of proceeds from the Offering, the Company continuing to grow its revenue and the Company building on the success of this past year. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Although the Company believes that the expectations reflected in these statements are reasonable, such statements are based on expectations, factors, and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond the Company's control, including but not limited to the risk factors discussed under the heading 'Risk Factors' in the Company's management's discussion and analysis, and elsewhere in this press release, as such factors may be further updated from time to time in our periodic filings, available at which factors are incorporated herein by reference. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results, or otherwise, or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.
The Guardian
13-05-2025
- Health
- The Guardian
Sneezing, snot and itchy eyes? Why nasal spray could be summer 2025's secret weapon
It's the most glorious time of year. The sun is shining, the weather is sweet, and nothing can stand in the way of the good times … well, almost nothing. Because sadly, there are two things guaranteed to try to put a damper on summer fun: one is rain, the other is hay fever. Obviously there's nothing any of us can do about the weather, but if you're one of the estimated one in four UK adults who suffers from hay fever, a nasal spray could be your secret summer weapon. Beconase Hay Fever Relief for Adults is the UK's number one hay fever relief nasal spray* that not only provides long-lasting relief from nasal congestion, sinus discomfort and watery eyes, but, in a 2024 survey, 99% agreed it was easy to use**. So don't let the outdoors hold you back this summer, here's how nasal spray could help you make the most of summer's finest moments … Something special happens as soon as summer arrives. Thanks to the increased sunlight, longer days, and warmer temperatures, we all get a physical and mental boost, and suddenly even the most uptight of us are laid back, looking on the bright side and up for adventure. But if you suffer from hay fever, your sunnies might not be quite so rose-tinted. Nasal congestion, watery eyes, runny nose, sneezing, itchy eyes, itchy nose, red eyes and sinus discomfort may take the spring out of your step. Luckily, Beconase nasal spray for adults helps tackle these common hay fever symptoms, which can get you on your way to being your easy, breezy summer self. Summer is a season of sensational smells. Just think about it: the sweet, smokey char of a barbecue wafting over the garden fence; a whiff of fragrant honeysuckle as you pass it on a sunny street; the warm, tropical scent of suntan lotion as you massage it into your skin – these evocative smells have the power to transport us through space and time. But if you suffer from hay fever, your nose might be too congested to catch these seasonal aromas, let alone bask in their daydream-inducing glory. Enter Beconase nasal spray, which works at the source to relieve hay fever symptoms in the nose and eyes. It contains beclometasone, which has an anti-inflammatory action; this means it reduces nasal inflammation and swelling too, adding to the relief you could experience. Breakfast, lunch, dinner … meetings? As soon as the mercury hits 25C all bets are off, and if an activity can conceivably take place outside, chances are someone will do it – or at least suggest it. Given that we've been holed up inside through the long, dark months of winter, this is completely understandable – but if you suffer from hay fever, alfresco living can feel hellish rather than wholesome. Summer '25 could be different though. Why? Well, Beconase nasal spray taken regularly can relieve the symptoms of hay fever and help you enjoy the great outdoors even if the pollen count is high. Now, where's that picnic at? A festival in the countryside, a picnic in your local park, a night out at a rooftop bar and a delicious dip at a secret wild swimming spot – all in one weekend? Sign us up! When the sun is shining, no one wants to miss a minute of the good times, and suddenly even the most dedicated of homebodies find themselves flitting from one social event to the next. Fortunately for hay fever sufferers, Beconase nasal spray is non-drowsy, so you don't have to choose between easing your symptoms and feeling on the ball. Instead, you can say an enthusiastic 'YES!' to every invitation that comes your way. Happy days! At the height of summer, on the longest day, we are treated to a whopping 16 hours of daylight – so it's no wonder that summer days can feel endless in the best possible way. For hay fever sufferers the good news is, Beconase nasal spray is long-lasting so can help to tackle symptoms even if you're out and about soaking up every last ray of sun. Beconase provides up to 24 hours' relief from hayfever symptoms when used twice a day; for best results, Beconase should be sprayed twice into each nostril every morning and night. Just think of it as your special, summer morning/bedtime routine. Buy Beconase now on Amazon *Based on IRI units data, 52 w/e 1st March 2025. To verify please contact verify@ **Home Tester Club Survey 2024. 102 participants. Data on file, to verify contact: verify@ Beconase Hayfever Relief for Adults 0.05% Nasal Spray contains beclometasone dipropionate. For the treatment of hay fever and symptomatic relief from nasal congestion, runny nose, sneezing, itchy nose, eye symptoms (such as itching, watering, redness) and associated sinus discomfort in adults aged 18 and over. Always read the leaflet. If your hay fever symptoms still haven't improved within seven days, speak to a doctor. MAT-9350
